ABSTRACT
The aim of this study was to evaluate face apraxia in left- and right-hemisphere-damaged patients both in the acute and chronic stage of their disease. Two newly devised tests that assess movements of the upper and lower face districts were employed. On the whole, the proportion of left-hemisphere-damaged patients showing face apraxia were 46 and 68% for upper and lower face, respectively. A substantial proportion of right-hemisphere-damaged patients also showed face apraxia, i.e. 44% upper face and 38% lower face. Concomitant variables such as general severity, locus of lesion, language or visuo-spatial impairments, presence of neglect, interval from stroke, peculiarity of clusters of items or scoring procedures did not account for these results. These findings suggest that face apraxia in some patients may affect movements of the upper face district and that the right hemisphere plays a significant part in both upper and lower face praxis.
Subject(s)
Apraxias/etiology , Brain Injuries/complications , Cerebral Cortex/physiopathology , Functional Laterality/physiology , Adult , Aged , Aged, 80 and over , Apraxias/pathology , Apraxias/physiopathology , Brain Injuries/pathology , Brain Injuries/physiopathology , Cerebral Cortex/injuries , Cerebral Cortex/pathology , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Psychomotor Performance/physiology , Stroke/complications , Stroke/pathology , Stroke/physiopathologyABSTRACT
Previous works have documented that pentagastrin has a stimulatory effect on salivary secretion. In this paper, we have studied the action of caerulein, a peptide that has an active gastrin-like terminal tetrapeptide, on salivary secretion in man. Our data documented that caerulein and pentagastrin have similar excitatory effect on gastric secretion in man, but different actions on salivary flow. Caerulein, at increasing doses, inhibits salivary flow, but not the secretion of amylase; this effect is statistically significant at 0.5 micrograms/kg/h which is the same dose that maximally stimulates gastric secretion. The inhibitory effect of caerulein was not reversed by previous injection of papaverin.
Subject(s)
Ceruletide/pharmacology , Salivary Glands/drug effects , Salivation/drug effects , Adult , Amylases/metabolism , Ceruletide/administration & dosage , Gastric Juice/metabolism , Humans , Male , Papaverine/pharmacology , Pentagastrin/pharmacology , Stimulation, ChemicalABSTRACT
To evaluate the effect of cerulein on salivary secretion in man, 25 healthy volunteers have been studied. In the morning, before breakfast, saline solution (125 ml/h) has been infused at a constant flow, for one hour. Saline solution has been followed, for other 60', by saline solution + Cerulein at doses of 0.05, 0.1, 0.2, 0.3, 0.5 microgram/Kg/h. These different doses have been administered in different days according to a randomized order. A wash out by saline solution, at same velocity as before, has been carried out after Cerulein . Samples of saliva were collected every 15'. On salivary specimens the amylase activity (U/l) has been dosed. Each dose of Cerulein induced a reduction of salivary flow. By blocking the administration of Cerulein the salivary secretion returned to basal value in about one hour. No inhibitory effect has been noted on amylase secretion using different doses of Cerulein .
